GlassScriptPhysician profile
Caitlin Fortune
NPI 1215437413
$16,162.10
in general payments reported to CMS, 2019-2025
34 companies · $2,956 in 2025
The $2,956 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $742 · 2022: $4,682 · 2023: $4,842 · 2024: $2,941 · 2025: $2,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,547.67 |
| Education | $190.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,867.30 | 2021-2025 | |
| Amgen INC. | $2,410.50 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $1,888.31 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $1,872.62 | 2021-2025 | |
| Ucb, INC. | $1,758.65 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $849.55 | 2022-2025 | Saphnelo |
| Radius Health, INC. | $814.69 | 2021-2025 | Tymlos |
| Lilly USA, LLC | $632.30 | 2021-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $446.05 | 2021-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $367.07 | 2022-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $335.30 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $319.10 | 2022-2025 | Orencia |
| Pfizer INC. | $288.80 | 2021-2025 | |
| Horizon Therapeutics Plc | $242.77 | 2022-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $125.52 | 2022-2025 | Strensiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.22 | 2022-2025 | Ofev, Cyltezo |
| Sandoz INC. | $96.72 | 2023-2025 | Hyrimoz, Jubbonti |
| Fresenius Kabi USA, LLC | $82.55 | 2023-2024 | Idacio |
| Depuy Synthes Sales INC. | $80.50 | 2024-2025 | Monovisc, Orthovisc, Peak |
| Mallinckrodt Hospital Products INC. | $76.83 | 2022-2023 | Acthar |
| Janssen Pharmaceuticals, INC | $71.44 | 2025 | Tremfya |
| Genentech USA, INC. | $66.75 | 2023-2025 | Actemra |
| Genzyme Corporation | $66.43 | 2023-2025 | |
| Kyowa Kirin, INC. | $66.32 | 2023-2024 | Crysvita |
| Hikma Pharmaceuticals USA | $31.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.91 | 2025 | Hyqvia |
| Cumberland Pharmaceuticals, INC. | $24.91 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $23.46 | 2023 | Zilretta, Iovera |
| Celltrion USA INC. | $22.65 | 2023 | Yuflyma |
| Fidia Pharma USA INC. | $21.71 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.74 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.59 | 2022 | |
| Medtronic, INC. | $13.46 | 2025 | Kyphon Express II Kyphopak Tray |
| Cranial Technologies, INC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Fortune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.